Research Article
Prognostic Significance of Pretreatment Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio in Patients with Diffuse Large B-Cell Lymphoma
Table 2
Univariate analysis of clinical factors for PFS and OS in 182 patients.
| Characteristics | OS | PFS | HR | 95%CI | P value | HR | 95%CI | P value |
| Age (>60) | 0.862 | 0.497-1.496 | 0.597 | 0.840 | 0.489-1.443 | 0.528 | Gender | 0.923 | 0.531-1.602 | 0.775 | 0.918 | 0.534-1.576 | 0.755 | B symptoms | 0.504 | 0.279-0.911 | 0.023 | 0.500 | 0.278-0.900 | 0.021 | ECOG PS (⩾2) | 0.427 | 0.231-0.788 | 0.007 | 0.497 | 0.271-0.912 | 0.024 | LDH (>ULN) | 0.405 | 0.232-0.707 | 0.001 | 0.385 | 0.222-0.667 | 0.001 | Stage (III and IV) | 0.527 | 0.301-0.921 | 0.025 | 0.574 | 0.331-0.993 | 0.047 | Bone marrow involvement | 2.227 | 0.945-5.252 | 0.067 | 0.506 | 0.215-1.191 | 0.119 | IPI (>2) | 0.379 | 0.216-0.665 | 0.001 | 0.420 | 0.241-0.732 | 0.002 | Extranodal sites of disease (>1) | 0.451 | 0.247-0.824 | 0.010 | 0.507 | 0.280-0.919 | 0.025 | Pathology type | 0.895 | 0.447-1.789 | 0.753 | 0.830 | 0.416-1.656 | 0.598 | NLR⩾150 | 1.909 | 1.066-3.418 | 0.030 | 0.527 | 0.298-0.932 | 0.028 | PLR⩾2.32 | 0.551 | 0.314-0.969 | 0.038 | 0.528 | 0.302-0.924 | 0.025 |
|
|
Abbreviations: NLR, neutrophil/lymphocyte ratio; PLR, platelet/lymphocyte ratio.
|